GE's Clarient expands with SeqWright purchase
GE Healthcare has acquired SeqWright, a developer of nucleic acid sequencing and other genomic services, to add complementary genomics capabilities to Clarient, a unit of GE Healthcare in the molecular diagnostics sector.
The deal also provides a platform for Clarient to expand its clinical diagnostic offerings to include next-generation sequencing. Financial terms of the acquisition were not disclosed.
“Understanding how genetic variation at the molecular level impacts disease is critical in the continued discovery and development of new and more effective therapies, and increasingly in the management of patient care through the use of more precise diagnostic tests,” said Pascale Witz, MA, MBA, president and CEO, GE Healthcare's medical diagnostics unit.
Aliso Viejo, Calif.-based Clarient provides pathologists and oncologists with access to diagnostic tests for various cancers by combining diagnostic technologies with pathology expertise to assess and characterize cancer. Clarient is focused on developing proprietary diagnostic markers and tests for the profiling of breast, lung, colon, melanoma and blood-based cancers.
The deal also provides a platform for Clarient to expand its clinical diagnostic offerings to include next-generation sequencing. Financial terms of the acquisition were not disclosed.
“Understanding how genetic variation at the molecular level impacts disease is critical in the continued discovery and development of new and more effective therapies, and increasingly in the management of patient care through the use of more precise diagnostic tests,” said Pascale Witz, MA, MBA, president and CEO, GE Healthcare's medical diagnostics unit.
Aliso Viejo, Calif.-based Clarient provides pathologists and oncologists with access to diagnostic tests for various cancers by combining diagnostic technologies with pathology expertise to assess and characterize cancer. Clarient is focused on developing proprietary diagnostic markers and tests for the profiling of breast, lung, colon, melanoma and blood-based cancers.